Biosimilars advancements: Moving on to the future.

Area of Science:

• Biopharmaceutical development
• Regulatory science
• Analytical chemistry

Background:

• Expiring patents for recombinant biologics and monoclonal antibodies (mAbs) are increasing global interest in biosimilars.
• Biosimilars are crucial for pharmaceutical industries worldwide, particularly in emerging economies needing access to biologic treatments.

Purpose of the Study:

• To review the evolution of biosimilar development, encompassing regulatory aspects, manufacturing bioprocesses, comparability studies, and market dynamics.
• To highlight the critical role of analytical characterization in establishing biosimilarity.

Main Methods:

• Review of global regulatory landscapes for biosimilars.
• Analysis of manufacturing bioprocesses and their impact on biosimilar development.
• Examination of analytical techniques for physicochemical and biological characterization.
• Discussion of Quality by Design (QbD) principles in biosimilar manufacturing.

Main Results:

• The global regulatory environment for biosimilars is continuously evolving.
• Analytical structure and functional analyses are foundational to biosimilar development programs.
• Demonstrating biosimilarity requires overcoming challenges in manufacturing and characterization compared to reference products.
• Advanced analytical tools and QbD approaches improve product quality, purity, safety, and efficacy.

Conclusions:

• The pursuit of biosimilarity has deepened the understanding of reference products and their manufacturing processes.
• Technological advancements in meeting regulatory and market demands for biosimilars are expected to spur innovation in biomanufacturing.
• Biosimilar development contributes to more efficient and productive manufacturing processes for biologic drugs.